Format

Send to

Choose Destination
J Bone Miner Res. 2018 Aug;33(8):1444-1449. doi: 10.1002/jbmr.3438. Epub 2018 May 17.

Hypomagnesemia During Teriparatide Treatment in Osteoporosis: Incidence and Determinants.

Author information

1
Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
2
Endocrinology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
3
Institut de Rhumatologie de Montréal, Montréal, Canada.
4
Nephrology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Canada.

Abstract

In our clinical experience, we have encountered patients who developed hypomagnesemia after the introduction of teriparatide. Some trials have reported hypomagnesemia as an adverse event during teriparatide treatment, but this issue had never been studied specifically. Our objective was twofold: 1) determine the incidence of hypomagnesemia (serum magnesium <0.7 mmol/L) associated with teriparatide in a retrospective cohort and 2) identify the predisposing factors to hypomagnesemia in this cohort. We reviewed the files of 53 patients treated for severe osteoporosis with teriparatide for 6 to 24 months between May 2008 and January 2016. Serum magnesium levels were measured at 0, 3, 6, 12, 18, and 24 months. In the full cohort, we observed an average decrease of serum magnesium of 0.075 mmol/L, 0.069 mmol/L, 0.085 mmol/L, 0.086 mmol/L (p < 0.001) at 3, 6, 12 months, and at the end of the treatment, respectively. The cumulative incidence of hypomagnesemia during treatment with teriparatide was 35.9% (19 patients). Patients' older age (71.1 versus 65.1 years; p = 0.05) and lower baseline level of magnesium before teriparatide treatment (0.81 mmol/L versus 0.85 mmol/L; p = 0.03) were significant risk factors for teriparatide-induced hypomagnesemia. The average decrease of serum magnesium was greater in the patients who developed hypomagnesemia compared with normomagnesemic patients at 3 months (0.110 mmol/L versus 0.054 mmol/L; p = 0.02), 6 months (0.139 mmol/L versus 0.036 mmol/L; p < 0.001), and 12 months (0.156 mmol/L versus 0.048 mmol/L; p < 0.001). Serum calcium, creatinine, and parathyroid hormone remained normal throughout the treatment period. We observed a statistically significant decrease in the serum magnesium levels in patients treated with teriparatide for severe osteoporosis. Older age and lower baseline magnesium were significant determinants of hypomagnesemia. Closer monitoring of serum magnesium level should be considered in these patients.

KEYWORDS:

HYPOMAGNESEMIA; OSTEOPOROSIS; TERIPARATIDE

PMID:
29637622
DOI:
10.1002/jbmr.3438

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center